The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase
(ALK) fusion gene occurs in approximately 5% of non-small-cell lung cancers (NSCLCs) …

According to the authors and editors, this report contains the most justified principles of
diagnostic and therapeutic procedures prepared, considering the scientific value of …

Background The development of anaplastic lymphoma kinase (ALK) tyrosine kinase
inhibitors (TKIs) has improved the survival outcomes of patients with advanced ALK …

Introduction We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2
(ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. Methods The phase 1/2 study …

目的从中国卫生体系角度出发, 评价劳拉替尼对比克唑替尼一线治疗间变性淋巴瘤激酶(ALK)
阳性晚期非小细胞肺癌的经济性, 为该药在我国除香港以外其他地区的产品定价及相关医疗决策 …

Non-small cell lung cancer (NSCLC) is a frequent type of cancer, which is mainly
characterized clinically by high aggressiveness and high mortality. KRAS oncoprotein is the …

Introduction In classical EGFR mutant non-small-cell lung cancer (NSCLC), EGFR tyrosine
kinase inhibitor (TKI) therapy yields better outcomes than platinum-based chemotherapy …

Background As the number of genetic mutations that must be tested increases, the
Oncomine Dx Target test (ODxTT), which can simultaneously detect multiple cancer‐related …

The emergence of tyrosine kinase inhibitors and immune checkpoint inhibitors has paved a
new era for the management of non‐small cell lung cancer, which has for many years lacked …

The concept of liquid biopsy as an analysis tool for non-solid tissue carried out for the
purpose of providing information about solid tumors was introduced approximately 20 years …